GenoLogics has raised $8 million in strategic financing led by new investor Illumina. The financing will be used to accelerate product development for future clinical applications and new desktop sequencing systems, and to expand sales and marketing functions.
Illumina senior vice president and chief commercial officer Tristan Orpin will also be joining GenoLogics' board of directors.
"This strategic investment in GenoLogics will benefit our mutual sequencing customers," said Illumina's Orpin. "We value the unique data management capabilities GenoLogics brings to our customers and the industry."